SCHEMBL32669418

SCHEMBL32669418

c1cc2c3c(ccc2[nH]1)OCO3

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 1/20 0.40
TTBK2 Q6IQ55 1/20 0.40
HTR1A P08908 2/20 0.39
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR1E P28566 1/20 0.39
HTR1F P30939 1/20 0.39
HTR7 P34969 1/20 0.39
HTR2B P41595 1/20 0.39
HTR3A P46098 1/20 0.39
HTR5A P47898 1/20 0.39
HTR6 P50406 1/20 0.39
HTR4 Q13639 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
NQO2 P16083 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3900178 0.86 ADRA2A (0.39) HTR1APTK2AHRALDH1A1KDM4E
SCHEMBL11437391 0.77 AHR (0.39) HTR1DHTR1BHTR6AHRMAPK1
SCHEMBL9739366 0.73 NQO2 (0.37) HTR1AHTR3EHTR3BHTR1DHTR1B
SCHEMBL5760174 0.72 QPCT (0.39) TTBK1TTBK2HTR1AHTR3EHTR3B
SCHEMBL7466691 0.71 HTR1A (0.48) HTR1AHTR2AHTR2CHTR2BPRKAA1
SCHEMBL7466700 0.71 HTR1A (0.48) HTR1AHTR2AHTR2CHTR2BPRKAA1
SCHEMBL19776164 0.71 NQO2 (0.49) HTR1AHTR3EHTR3BHTR1DHTR1B
SCHEMBL2398840 0.69 AHR (0.52) HTR1DHTR1BHTR6AHRMAPK1
SCHEMBL1978270 0.69 MEN1 (0.41) HTR1AHTR1DHTR1BHTR2AHTR2C
SCHEMBL9741484 0.68 HTR3E (0.37) HTR1AHTR3EHTR3BHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034119-A1 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS HTR4, OPRM1, HTR7 TTBK1 4093/4885TTBK2 3538/4885HTR1A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.